DDX53 and neoplasm: Although the differences were not statistically significant, anti-CD25 antibody treatment tended to suppress tumor growth in CT26-mock tumors and promote tumor growth in CT26-ULBP2 tumors compared to the isotype control antibody group (Figure 4B,C).